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Small intestinal cannabinoid receptor changes following a 
single colonic insult with oil of mustard in mice
Edward S. Kimball†, Nathaniel H. Wallace, Craig R. Schneider, Michael R. D’Andrea and Pamela J. Hornby*
Johnson & Johnson Pharmaceutical Research and Development, LLC, Spring House, PA, USA
Cannabinoids are known to be clinically beneficial for control of appetite disorders and nausea/
vomiting, with emerging data that they can impact other GI disorders, such as inflammation. 
Post-inflammatory irritable bowel syndrome (PI-IBS) is a condition of perturbed intestinal 
function that occurs subsequent to earlier periods of intestinal inflammation. Cannabinoid 1 
receptor (CB1R) and CB2R alterations in GI inflammation have been demonstrated in both 
animal models and clinically, but their continuing role in the post-inflammatory period has only 
been implicated to date. Therefore, to provide direct evidence for CBR involvement in altered GI 
functions in the absence of overt inflammation, we used a model of enhanced upper GI transit 
that persists for up to 4 weeks after a single insult by intracolonic 0.5% oil of mustard (OM) in 
mice. In mice administered OM, CB1R immunostaining in the myenteric plexus was reduced 
at day 7, when colonic inflammation is subsiding, and then increased at 28 days, compared to 
tissue from age-matched vehicle-treated mice. In the lamina propria CB2R immunostaining 
density was also increased at day 28. In mice tested 28 day after OM, either a CB1R-selective 
agonist, ACEA (1 and 3 mg/kg, s.c.) or a CB2R-selective agonist, JWH-133 (3 and 10 mg/kg, 
s.c.) reduced the enhanced small intestinal transit in a dose-related manner. Doses of ACEA 
and JWH-133 (1 mg/kg), alone or combined, reduced small intestinal transit of OM-treated mice 
to a greater extent than control mice. Thus, in this post-colonic inflammation model, both CBR 
subtypes are up-regulated and there is increased efficacy of both CB1R and CB2R agonists. 
We conclude that CBR remodeling occurs not only during GI inflammation but continues 
during the recovery phase. Thus, either CB1R- or CB2-selective agonists could be efficacious 
for modulating GI motility in individuals experiencing diarrhea-predominant PI-IBS.
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and Brown, 2000; Coutts et al., 2002; Pertwee and Ross, 2002; Casu 
et al., 2003). Immune cells in the intestinal lamina propria express 
CB2R, including plasma cells and activated macrophages (Wright 
et al., 2005).
In normal GI motility states, there is substantial experimental 
evidence that CB1R inhibits contractility and GI motility at multi-
ple levels, reviewed in (Izzo and Sharkey, 2010). An enhanced role 
of CB1R has been reported in a number of rodent GI inflammatory 
models. For example, in mice with colitis induced by intracolonic 
dinitrobenzene sulfonic acid (Sibaev et al., 2006) and with ileitis-
induced small intestinal croton oil (Izzo et al., 2001). Compared to 
CB1R, there is little evidence that CBR2 is involved in the control 
of normal GI motility, although CBR2 tonic inhibitory activity via 
endogenous cannabinoids has been reported in rat stomach (Storr 
et al., 2002), but not mouse stomach (Mule et al., 2007). However, 
in inflamed mice and rats models, there is now clearly an inhibitory 
role of CB2R in GI motility. For example, CB2R up-regulation and 
inhibition of GI transit have been reported in models of inflam-
mation such as, croton oil-induced diarrhea (Izzo et al., 2000), 
trinitrobenzene sulfonic acid (TNBS)-induced colitis (Storr et al., 
2009) and lipopolysaccharide (LPS)-induced GI transit in vivo and 
in isolated segments of ileum (Mathison et al., 2004; Duncan et al., 
2008). Interestingly, in LPS-treated rat tissue, CB2R is localized in 
IntroductIon
Debate about the medical benefits of cannabinoids in a wide array 
of diseases is based on anecdotal evidence from patients who have 
used medical marijuana, experimental animal models, and an 
increasing number of clinical studies. In gastrointestinal (GI) dis-
eases there is overwhelming evidence that cannabinoids increase 
appetite and improve weight gain in patients during cancer chemo-
therapy or those suffering from AIDS wasting syndrome. However, 
as reviewed recently (Izzo and Sharkey, 2010), cannabinoids in the 
gut modulate gastric secretion and gastroprotection, GI motility, 
ion transport, visceral sensation, intestinal inflammation, and cell 
proliferation. In addition, evidence is emerging that exogenous and 
endogenous cannabinoids, have an important role in pathophysiol-
ogy, such as in GI inflammation (D’Argenio et al., 2007; Izzo and 
Camilleri, 2009).
The primarily active constituent of marijuana, ∆9-tetrahydro-
cannabinol, acts on cannabinoid 1 (CB1R) and 2 (CB2R) recep-
tors, which are G-protein coupled receptors (Glass and Northup, 
1999; Bosier et al., 2010). There is a differential localization and 
distribution of CBR, where CB1R is located primarily on neuronal 
tissue and CB2R is located on peripheral blood leukocytes. In the 
GI tract, CB1R highly expressed in the submucosal and myenteric 
plexus neurons, as well as visceral afferent nerves (Kulkarni-Narla 
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held vertically in a head down position so that 50 μl of a solution of 
0.5% OM in 30% ethanol could be administered intracolonically. 
The OM administration occurred to a depth of 4 cm via a syringe 
equipped with a ball-tipped 22 G needle. The mice were allowed 
to recover from anesthesia under a warming light, and then were 
maintained with normal feed and water for 28 days at which time 
they were tested for small intestinal transit rate.
drug treatment
Cannabinoid agonists arachadonyl chloroethyl amide (ACEA), and 
JWH-133 (Tocris-Cookson, St. Louis, MO, USA) were administered 
subcutaneously, 30 min prior to carmine dye (cochineal powder; 
Sigma-Aldrich St. Louis, MO, USA) administration. In all experi-
ments, CBR agonists were dissolved in a vehicle consisting of 5% 
Tween 80, 5% ethanol, and 5% dextrose in water. Drug-treated 
groups were compared against an OM control, which was admin-
istered vehicle only. The doses of agonists (ACEA and JWH-133) 
used in the present study were similar to that shown to be selectively 
acting at CB1R and CB2R in mice (Arevalo-Martin et al., 2003; 
Mathison et al., 2004).
upper gI transIt
Mice received 250 μl of a 6% solution of carmine dye in 0.5% 
methylcellulose (w/v) by oral gavage. After 20 min, the mice were 
rapidly euthanized by cervical dislocation according to accepted 
procedures. The large and small intestines were resected, starting 
with the distal colon first, and working toward the pylorus until 
the entire small intestine, cecum, and colon were removed intact. 
Excess connective tissue was trimmed, the resected bowel was 
arranged lengthwise without being stretched, and the length of 
the entire small intestine was recorded. Percent transit was deter-
mined to be the distance that the carmine dye front traveled and 
then converted into a percentage of the length of the entire small 
intestine. For some comparisons values were normalized to their 
own respective non-drug-treated (i.e., vehicle) control group whose 
transit rate was set as 100% of control. Transit was compared in 
OM-treated mice vehicle-treated and naïve age-matched controls. 
Mice were not fasted prior to gavage and all were feeding nor-
mally at the start of the experiment. In pilot experiments with this 
model we determined that food deprivation has no effect on transit 
measured by carmine red. Potential inter-animal variability in the 
severity of colitis and small intestinal transit induced by OM were 
inconsequential for N = 12–15 per experimental treatment group, 
as previously reported (Kimball et al., 2005). When results were 
combined from multiple experiments each experimental treatment 
group contained data from multiples of N = 12–15. Throughout 
the text small intestinal transit is used interchangeably with upper 
GI transit though it is  recognized that both gastric  emptying and 
small bowel transit contribute to the distance traveled down the 
small intestine.
ImmunohIstochemIstry
CB1R- and CB2R immunostaining was performed in 5 cm-long 
jejunoileal tissues, starting 5 cm proximal of the cecum. Tissues 
were collected from untreated mice, and from mice 7 and 28 days 
after OM-treatment. The tissues were formalin-fixed, and paraffin-
embedded prior to immunohistochemical treatments. Briefly, 5 μm 
enteric neurons (Duncan et al., 2008) and in inflammatory bowel 
disease patients (Wright et al., 2005) CB2R is expressed on intestinal 
epithelium. Both of these are cell types that do not typically express 
CB2R in normal tissue and suggests extensive CBR remodeling 
in GI inflammation in diseased human tissue and experimental 
animal models.
There is also human genetic evidence of CBR in GI-related dis-
orders. A frequent silent mutation is a common polymorphism 
(1359 G/A) of the CB1R gene (CNR1) in Caucasians (Gadzicki 
et al., 1999). This has been associated with metabolic syndrome in 
a Chinese population (Hu and Feng, 2010) and with irritable bowel 
syndrome (IBS) in Korean patients (Park et al., 2010). Although 
endocannabinoids and CBR have been linked to the underlying 
physiological processes of IBS (Storr et al., 2008), the association 
to the CNR1 gene is the first evidence linking CBR to IBS, to our 
knowledge. According to the Rome II and III criteria (Drossman, 
2007), IBS is a spectrum of disorders characterized by abdominal 
discomfort and increased pain perception associated with altered 
bowel habits. Animal models of IBS have focused on the pain com-
ponent and demonstrated that CBR agonists ameliorate visceral 
hyperalgesia during colorectal distention (Sanson et al., 2006; 
Brusberg et al., 2009) with increased efficacy after intracolonic 
TNBS (Kikuchi et al., 2008). However, there is little direct experi-
mental evidence suggesting that cannabinoids may be beneficial 
for the dysmotility of IBS.
We have characterized a mouse model of accelerated transit 
(Kimball et al., 2005) that persists after the resolution of colonic 
inflammation (Kimball et al., 2006). In this mouse model, intra-
colonic oil of mustard (OM) produces an acute (3 day) colitis 
(Kimball et al., 2006) that is associated with an early increased 
mRNA expression of soluble inflammatory mediators and cytokine 
levels in the colon (Kimball et al., 2007). During the inflammatory 
stage, CB1R mRNA is rapidly up-regulated by 6 h but then down-
regulated 2–3 days after OM (Kimball et al., 2007). After these 
inflammatory changes have resolved, mice exhibit increased small 
bowel transit 4 weeks after the initial insult (Kimball et al., 2005). 
Since this model may provide insight into CBR in the underlying 
pathophysiology of post-inflammatory IBS (PI-IBS), and we do 
not know the role of cannabinoids at this stage in the model, we 
used it to examine the time course of expression of CB1R and 
CB2R immunostaining in mouse small bowel following OM colitis 
induction, as well as compare the effects of cannabinoid agonists 
on intestinal transit after resolution of colonic inflammation.
materIals and methods
Male CD-1 mice (Charles River Laboratories, Kingston, NC, USA), 
10- to 12-weeks old, were used throughout these studies. All treat-
ments were carried out in accordance with the Federal Animal 
Welfare Act and with methods approved by the Institutional Animal 
Care and Use Committee of Johnson and Johnson Pharmaceutical 
Research and Development, LLC.
InductIon of colItIs
Freshly opened OM (95 or 98% pure allyl isothiocyanate, Sigma-
Aldrich St. Louis, MO, USA), was used in each experiment. Mice 
(N = 12–15 per drug or vehicle treatment group) were briefly anes-
thetized with ketamine/xylasine (Sigma, St. Louis, MO, USA), and 
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and day 7 post-OM administration tissues (Figure 1D), but were 
strongly positive and abundant 28 days post-OM administration 
(Figure 1F). Positively stained cells in the lamina propria appeared 
to be mononuclear (Figure 1F inset), but further work would be 
required to identify specific cell type.
Semi-quantitative analysis of the changes in CB1R- and CB2R 
staining, by someone blinded as to treatment, illustrate these time 
dependent observations (Figure 2). Compared to untreated tissue, 
at day 7 post-OM tissues contained significantly fewer ganglia with 
moderate and intense CB1R + ve neuronal staining, whereas at day 
28 post-OM these were significantly increased (Figure 2A). The 
number of villi with > 5 CB2R + ve cells in lamina propria cells was 
significantly increased at 28 days post-colitis (Figure 2B).
In a separate group of animals small intestinal transit studies 
were performed with CBR agonists administered to mice 28 days 
after intracolonic vehicle (30% ethanol) or OM. As expected from 
our earlier study (Kimball et al., 2005), normal untreated mice 
upper GI transit (56 ± 2 and 56 ± 2% of small bowel length) was 
less than in mice 28 days after treatment with intracolonic OM 
(71 ± 2 and 68 ± 2% of small bowel length). Administration of the 
CB1R-selective agonist ACEA (1 and 3 mg/kg) to OM-treated mice 
effectively reduced the enhanced small intestinal transit to 59 ± 2 
and 58 ± 4%, respectively, resulting in upper GI transit similar to 
that in normal mice (Figure 3A). Administration of the CB2R-
selective agonist JWH-133 (3 and 10 mg/kg, s.c.) to OM-treated 
mice also reduced small intestinal transit to 49 ± 3 and 53 ± 4%, 
respectively. In this case, upper GI transit after CB2R agonist (3 mg/
kg) administration in OM-treated mice appeared lower than that 
of normal mice but this was not reproduced at the highest dose 
(10 mg/kg; Figure 3B).
In Figures 3C,D, all values for upper GI transit in CBR-treated 
mice were normalized to their respective CBR vehicle-treated con-
trol group, to enable comparison of CBR agonists in both intraco-
lonic OM-and vehicle-treated mice. This illustrates a dose-related 
inhibition of accelerated transit in OM-treated mice by both CBR 
agonists. In intracolonic vehicle-treated control mice there was no 
effect of increasing doses of ACEA (Figure 3C). There was a trend 
for JWH-133 to increase upper GI transit in intracolonic vehicle-
treated group (Figure 3D); however, the apparent increases did not 
attain the acceptable level of statistical significance.
Small intestinal transit is stable in normal (untreated) mice and 
those administered intracolonic vehicle (30% ethanol) after 28 days 
(Figure 4). Administration of the CB1R-selective agonist, ACEA, or the 
CB2R-selective agonist, JWH-133, individually at 1 mg/kg inhibited 
transit in OM-treated mice, but had no significant effect in normal 
mice (Figure 4). When the doses were combined they reduced the 
distance the marker traveled down the intestine to 65 ± 6 and 49 ± 7% 
of total length in normal and OM-treated mice, respectively (P < 0.001 
compared to their respective controls). Although there was a trend to 
greater inhibition by the combination of CBR agonist in OM-treated 
mice this was not different than the same treatment in normal mice.
dIscussIon
In the present study we have made the novel observations that 
CB1R in myenteric neurons and CB2R immunostaining in lamina 
propria are altered in the small intestine of mice up to 4 weeks 
after intracolonic OM. These changes are observed not only in 
tissue sections were mounted on microscope slides and then rou-
tinely dewaxed and rehydrated. After a 5 min exposure in a micro-
wave in Target Buffer (Dako, Carpinteria, CA, USA), slides were 




 for 5 min, followed by treatment 
with avidin–biotin reagent (Serotec, Raleigh, NC, USA) to elimi-
nate endogenous peroxidase and biotin activity, respectively. The 
slides were then routinely processed for immunohistochemistry. 
All incubations were performed at room temperature for 30 min. 
After a 10 min blocking step with normal goat serum, the tissues 
were incubated with the primary antibodies. Rabbit anti-CB1R 
(1:20 dilution) and rabbit anti-CB2R (1:2 dilution; Chemicon, 
Temecula, CA, USA) polyclonal antibodies were used to identify 
CBR-immunoreactivity in tissue sections. Biotinylated goat anti-
rabbit secondary antibody (Vector Labs, Burlingame, CA, USA), 
avidin–horseradish peroxidase (AbD Serotec, Raleigh, NC, USA) 
and 3,3′diaminobenzidine (Biomeda Foster City, CA, USA) used to 
detect immunostaining. Staining controls lacked primary antibod-
ies, but included all other reagents. Since both primary antibodies 
were rabbit polyclonals the same staining controls could serve for 
both CB1R and CB2R, as reported in previous studies using these 
antibodies (Kimball et al., 2006).
Semi-quantitative analysis of CB1R- and CB2R staining was 
performed by a histologist who was blinded as to the treatment. 
For CB1R immunostaining myenteric ganglia were counted in the 
entire section (N = 8 sections) using a 40X objective, and assigned 
as weak-negative, moderate or intense staining. CB2R + ve cells in 
lamina propria were quantified as number of villi from eight high-
powered fields showing either fewer or greater than five positively 
stained cells in the LP.
statIstIcs
Experimental groups were analyzed for significance of differ-
ences between the means of treatment groups and control groups 
by ANOVA with Bonferroni’s post-test using GraphPad Prism 
(GraphPad Software, San Diego, CA, USA). A P-value < 0.05 was 
considered statistically significant.
results
CB1R and CB2R immunostaining was analyzed in jejunoileal tis-
sues from normal mice and OM-treated mice taken 7 and 28 days 
after OM colitis induction. These times were based on our previ-
ous work, where at day 7 mice showed no alterations in intestinal 
transit with diminished inflammation in the large intestine and at 
day 28 mice had no inflammation but increased transit (Kimball 
et al., 2005). Representative photomicrographic images illustrate 
the marked changes observed in CB1R and CB2R immunostaining 
noted in myenteric ganglia and lamina propria (Figure 1). CB1R 
immunostaining in myenteric ganglia was moderately intense 
in untreated mouse tissue (Figure 1A) compared with little to 
no staining observed in tissues 7 days after OM administration 
(Figure 1C). However, by day 28 post-OM treatment (Figure 1E), 
more intense CB1R immunostaining was visualized in myenteric 
ganglia neurons, which appeared to exceed that seen in normal 
tissues. The myenteric ganglia also appeared to be larger in size, 
though size of ganglia was not quantified. CB2R immunostaining 
was most notably changed in the lamina propria. Lamina pro-
pria CB2R + ve cells were low to absent in untreated (Figure 1B) 
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 cooperativity between CB1R and CB2R and amplification of signal-
ing in a perturbed post-inflammatory system. Altogether these data 
suggest that altered CBR responsiveness is maintained long after an 
initial inflammatory period, and suggest a role in the underlying 
pathophysiology of PI-IBS.
We have previously characterized this model during acute 
inflammation (Kimball et al., 2006) and used it to determine the 
effects of CBR agonists in colitis (Kimball et al., 2006). We selected 
this model to study the CBR changes in post-inflammatory condi-
the immediate post-colitis period (7 days) but also after all overt 
signs of inflammation have resolved (4 weeks) in mice that exhibit 
increased upper GI transit, which is a symptom consistent with 
clinical pathophysiology of PI-IBS (Kimball et al., 2005). Our results 
also demonstrate that both CB1R and CB2R agonists normalize 
upper GI transit in the OM-treated model and that the effect of 
these agonists is enhanced in the pathophysiological model com-
pared to normal mice. The differences in efficacy by CBR  agonists 
in the post-inflammatory compared to normal are  consistent with 
Figure 1 | immunohistochemical staining of small intestine tissues for 
CBr expression. Neuronal staining in myenteric plexus in normal controls (A), 
day 7 post-OM (C) and day 28 post-OM (e). Black arrows indicate myenteric 
ganglia. Moderate staining was observed in normal controls, deeply reduced at 
day 7, and restored to higher levels of expression at day 28. 
Immunohistochemical staining of small intestine tissues for CB2R expression is 
shown for lamina propria (LP) cells. Red arrows indicate stained cells in LP. LP 
cell staining is shown for normal controls (B), day 7 post-OM (D) and day 28 
post-OM (F). Dense CB2R +  staining was observed in numerous cells in day 28 
tissues, but not in untreated or in day 7 tissues. Inset (F) was enlarged to 
highlight CB2R +  LP cells with monocytic appearance. Non-specific staining in 
tissue where primary antiserum was omitted (g).
www.frontiersin.org November 2010 | Volume 1 | Article 132 | 5
Kimball et al. Cannabinoid receptor changes after intestinal insult
Figure 2 | (A) The number of myenteric ganglia in jejunoileal tissue with 
moderate (gray bars) and intense (black bars) CB1R-stained neurons are 
decreased at day 7 and increased at day 28 compared to untreated tissue. 
Changes in the number of ganglia in which CB1R staining was absent (clear 
bars) were not significantly different in post-OM compared to untreated tissue. 
(B) The number of villi with < 5 CB2R + ve cells (clear bars) compared to > 5 
CB2R + ve cells (black bars) in lamina. Differences two-way ANOVA and by 
Bonferroni’s post-test as a function of time were statistically significant and are 
shown as *P < 0.05, **P < 0.01, *** P < 0.001 compared to corresponding 
column for untreated.
Figure 3 | effects on small intestinal transit of a range of doses of CB1r (A,C) 
and CB2R agonists (B,D) in mice 28 days after intracolonic 0.5% OM, vehicle (30% 
ethanol) and normal (untreated) age-matched mice. In (A) and (B) the % small 
intestinal distance traveled by carmine red is illustrated, with statistical 
comparisons to intracolonic vehicle-treated mice (i.e., first column in A, B). Effective 
doses (1 and 3 mg/kg) ACEA in OM-treated mice resulted in less upper GI transit 
than control (OM-treated only) mice and transit distance was similar to normal 
mice. Both ACEA (C) and JWH-133 (D) decrease transit in a dose-related fashion, 
when the values for CBR-treated groups are normalized to % of vehicle-treated 
control mice within each treatment. * P < 0.05, ** P < 0.01, ***P < 0.001.
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situation that occurs in acute inflammation-induced hypermotil-
ity, reviewed in (Izzo, 2004; Wright et al., 2008; Izzo and Camilleri, 
2009), where CB2R are increased in sensitivity compared to little 
or no effect in normal tissue. For example, upregulation of CB2R 
contributed to the increased efficacy of non-selective CBR agonists 
(Izzo et al., 2000, 2001) and a CB2R agonist reduced the electri-
cally evoked ileal twitch responses in LPS-treated, but not normal, 
tissue (Duncan et al., 2008) and reduced motility in ileitis, but not 
in control mice (Capasso et al., 2008). Furthermore, a protective 
role of the CB2R in inflammation is demonstrated by a study in 
which a CB2R-selective antagonist exacerbated colitis (Storr et al., 
2009). It is possible that CB2R is limiting the extent of enhanced 
transit in the post-inflammatory condition, but this has not been 
tested yet.
Up-regulation and enhanced anti-transit effects of CB1R 
agonists were also noted in the present study. Previously CB1R 
agonists inhibited inflammation in OM-induced acute colitis 
(Kimball et al., 2006) and dinitrobenzene sulfonic acid-induced 
colonic inflammation (Massa et al., 2004) with enhanced effects 
of CBR agonists reducing intestinal transit, fluid accumulation 
or the rate of colonic expulsion in rodents who were given an 
inflammatory stimulus (Izzo et al., 2000, 2001, 2003; Izzo, 2004; 
Mathison et al., 2004). Therefore our data support this enhanced 
role of CB1R in pathophysiology of the gut and show that it is 
maintained during the post-inflammatory period. In our study 
in normal mice, the CB1R-selective agonist (ACEA 1 mg/kg) did 
not inhibit transit in normal mice, in contrast to the situation in 
normal rats (Mathison et al., 2004). Two differences are appar-
ent in these studies - species (rats versus mice) and the method 
of drug administration (i.p. versus s.c.). Discrepancies in CBR 
efficacy to inhibit gastric contractility has reported previously in 
rat (Storr et al., 2002) and mouse (Mule et al., 2007) stomach. 
tions because OM induces physiological perturbations similar to 
those associated with IBS, such as altered motility (Kimball et al., 
2005) and visceral hyperalgesia (Laird et al., 2001). In addition, 
early changes in CBR mRNA expression was noted in OM-induced 
colitis (Kimball et al., 2007), but this had not been confirmed by 
protein staining for longer time periods after the acute colitis. 
Finally, CBR signaling is a consequence of OM neuronal stimula-
tion (Bereiter et al., 2002) and seems to modulate the resulting 
hyperlagesia. Specifically, CBR interacts with TRPV1 channels on 
sensory afferents to ameliorate OM-induced hyperalgesia (Jordt 
et al., 2004; Akopian et al., 2008; Sawyer et al., 2009). Therefore this 
appears to be a useful model to study the role of CBR signaling in 
some of the pathophysiology associated with IBS.
We did not confirm selectivity of the CBR agonists in these experi-
ments by using selective antagonists. This is because many studies 
have used CB1R and CB2R agonists, including ACEA and JWH-133, 
and already characterized their subtype selectivity using receptor 
antagonists or the CB1R inverse agonist in models of inflamed gut 
(Izzo et al., 1999, 2000, 2001, 2003; Landi et al., 2002; Mathison et al., 
2004). The doses of agonists (ACEA and JWH-133) used in the present 
study were similar to that shown to be selectively acting at CB1R and 
CB2R to reduce rat LPS increased transit (Mathison et al., 2004). 
We recognize that without  demonstrating competitive inhibition by 
using selective CB1R and CB2R antagonists in this study, we cannot 
completely exclude non-target related effects of the agonists such 
as TRPV1 receptors that bind endocannabinoids, and which ACEA 
structurally resembles. However, ACEA and JWH-133 has not been 
tested against TRPV1 or other TRPs, nor has the TRP-family receptor 
has been implicated in controlling small intestinal motility.
Twenty-eight days after OM administration we observed an 
up-regulation of CB2R in the small intestine and an inhibition of 
enhanced upper GI transit by CB2R agonists. This is similar to the 
Figure 4 | intracolonic 30% ethanol had no impact on upper gi transit, 
measured 28 days later, compared to wild-type controls. CB1R (ACEA 
1 mg/kg) and CB2R (JWH-133, 1 mg/kg) agonists alone inhibited small 
intestinal transit in mice 28 days post-OM administration, but not in control 
mice. A combination of both agonists inhibited transit in both groups. All 
values were normalized to the appropriate control group mice (i.e., columns 
1–5 were normalized to mean transit in normal mice and columns 6–8 were 
normalized to mean transit in OM-treated treated mice) and are represented 
as % of control. ***P < 0.001 versus appropriate control (normal or 30% 
ethanol intracolonic).
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